AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT03387683
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Long-term Observational Study of the Safety of Roflumilast
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 135856
- Registration Number
- NCT03381573
- Locations
- 🇸🇪
Research Site, Solna, Sweden
A Study to Evaluate the Symptoms Over 24 Hours in Patients With Chronic Obstructive Pulmonary Disease - LASSYC Study
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 602
- Registration Number
- NCT03381560
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
Treatment and Exacerbation in COPD Subjects
Completed
- Conditions
- Comparative Effectiveness Study
- Interventions
- Other: Standard of Care
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60243
- Registration Number
- NCT03375450
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
Completed
- Conditions
- Asthma
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4519
- Registration Number
- NCT03373045
- Locations
- 🇵🇷
Research Site, Guaynabo, Puerto Rico
Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT03371459
- Locations
- 🇺🇸
Research Site, Medford, Oregon, United States
AZD8601 Study in CABG Patients
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT03370887
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT03368235
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 86
- Registration Number
- NCT03364608
- Locations
- 🇺🇸
Research Site, El Paso, Texas, United States
Indian Phenotype Registry
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40000
- Registration Number
- NCT03363594
- Locations
- 🇮🇳
Research Site, Goa, India
© Copyright 2025. All Rights Reserved by MedPath